Background
==========

Prostate cancer (PCa) is one of the leading causes of death among men in Europe and the United States \[[@B1],[@B2]\]. For localized PCa, several therapeutic options can be proposed to the patients in a curative intent, and as a result there is considerable controversy about whether conservative treatments give better results than non-conservative treatments. At diagnosis, the selection of patients for treatment is based on clinical characteristics (i.e. age, results from digital rectal examination, PSA value and TRUS-based sextant-biopsy), which may lead to either under or over-treatment.

With radical prostatectomy (RP) alone, 30% to 50% of the PCa patients will suffer from biochemical failure \[[@B3]-[@B5]\]. Improved staging methods including preoperative MRI to predict the risk of extracapsular extension, seminal vesicle involvement or positive margin and advances and improvements in surgical techniques and procedures have contributed to the use of RP in intermediate- or high-risk patients \[[@B5],[@B6]\]. In the case of high-risk features revealed in the examination of pathological specimens assessment, adjuvant radiotherapy (aRT) is a standard approach, and has led to acceptable and encouraging rates of 5-year biochemical-relapse free survival ranging between 72% and 74% \[[@B7],[@B8]\]. Even salvage radiotherapy (sRT) for biochemical failures, when delivered early after biochemical failure (i.e. PSA \< 0.5 ng/mL), gives acceptable rates of 5-year biochemical-relapse free survival \[[@B9]\]. In the context of a risk-adapted multimodal approach, 10-year cancer-specific survival rates that can be reached range between 88% and 92%, so that it is now widely accepted that this strategy including postoperative radiotherapy with or without androgen deprivation therapy (ADT) is one of the standards of care for patients with high-risk disease \[[@B8],[@B10]\].

With an adequate dose of radiation (≥ 72 Gy), exclusive radiotherapy seems to be comparable to RP in terms of biochemical control \[[@B11]-[@B14]\]. Nevertheless, although several randomized trials have confirmed that patients with PCa treated with exclusive 3D conformal radiotherapy benefit from dose escalation, late toxicity have also significantly increased in parallel \[[@B15]-[@B17]\].

Technological advances such as IGRT and IMRT have been developed, thereby allowing dose escalation to the prostate with reduced toxicity and maintained biochemical control \[[@B18],[@B19]\]. The use of combined IMRT and IGRT (IG-IMRT) is rapidly growing, when the prostate has not been removed. Very low rates of toxicity with high rates of 5-year biochemical control have been reported with IG-IMRT \[[@B18],[@B20]\].

Although there is considerable controversy about the best treatment for localized prostate cancer, whatever the risk group, the advent of IMRT and IGRT worldwide prompted us to carry out a pragmatic study to compare the impact of RP followed by postoperative IMRT with exclusive IG-IMRT in a matched-pair analysis based on risk-groups as determined preoperatively.

Methods
=======

Patients
--------

Between 01/2002 and 12/2009, 178 with localized PCa were referred for exclusive radiotherapy (IG-IMRT). In the same period and following RP, 69 patients were referred for aRT or early sRT without image guidance (RP + IMRT).

All of the patients underwent a prior bone scan and pelvic CT scan to rule out nodal and/or distant disease. Patients with a risk of nodal involvement at diagnosis had to undergo pelvic lymph node dissection for nodal staging if their risk was 15% or higher. As MRI and MR spectroscopy are now recognized ways to improve PCa detection and mapping and staging, all of the patients underwent a baseline MRI with combined MR spectroscopy at 3 Tesla to detect extra-capsular extension or seminal vesicle invasion, both of which could preclude for surgery, thus improving T-staging and the selection of high-risk patients before treatment. Pretherapeutic trans-rectal ultra-sound-based sextant biopsies (≥ 6 cores) with a validated and standardized procedure were also performed. Patients were matched one to one according to the baseline risk group as defined by D'Amico's classification assessed before exclusive radiotherapy or surgery.

After approval from the Institutional Review Board of the Georges François Leclerc Cancer Center, a total of 98 patients were matched (49:49).

Postoperative IMRT (n = 49)
---------------------------

Patient repositioning was performed daily based on skin-marks alignment. Thereafter, two orthogonal 2D images were acquired to use bony landmarks as the standard reference for repositioning before treatment with on-board electronic portal imaging (ePID). These were matched with related Beam's Eye Views as determined on the 3D planning CT through days 1 to 3 to correct for set-up uncertainties, and then checked weekly until completion of radiotherapy.

Exclusive IG-IMRT (n = 49)
--------------------------

Daily image guidance was performed using a 3D US-based system (Son Array®, Varian Medical Systems). The technique for US-based image guidance used in our institution has been described in detail elsewhere \[[@B21]\].

Follow-up
---------

Follow-up evaluations after treatment were performed at intervals of 3 to 6 months for 5 years and then annually. Each evaluation included digital rectal examination, PSA value and an evaluation of toxicity. Late toxicity was scored retrospectively according to the Common Toxicity Criteria Adverse Events version 3 (CTCAE v.3.0) morbidity grading scale.

Statistics
----------

To evaluate the efficacy of the two radiotherapy scheme (exclusive IG-IMRT vs. RP + postoperative IMRT), patients were matched one to one according to their baseline risk group (as defined using the classification of D\'Amico) before any treatment. Differences between subgroups were calculated using a Chi-square or an exact Fischer test for categorical data and using Student's test or Kruskall Wallis test for continuous data.

In the RP + IMRT group, two definitions of a biochemical failure were tested : a PSA ≥ 0.1 ng/mL followed by a consecutive rising PSA value and a PSA ≥ 0.2 ng/mL followed by a consecutive rising PSA value. In the exclusive IG-IMRT group, biochemical failure was defined by the Phoenix definition (nadir of PSA + 2 ng/mL). The rate of freedom from failure (FFF) was defined as the time between the first day of any treatment and the date of biochemical failure using the Kaplan Meier method. Patients were censored at last follow-up or death without relapse. The log-rank statistic was used to test for differences between groups. Univariate analysis was used to determine the predictive factors for time to biochemical relapse (using Cox proportional hazard ratio model) and for late toxicities (using Logistic Regression).

P values were two-sided and considered significant when lesser than 0.05. All of the analyses were performed using STATA V11 software (STATA Corp, College Station, TX).

Results
=======

Unsurprisingly, patients in the RP + IMRT group were more likely to be younger than patients selected for exclusive IG-IMRT (p \< 0.001). At baseline, the matched patients were more likely to have a low- or intermediate-risk disease. The characteristics of the patients, the tumors and treatment with respect to the treatment arm are summarized in Table [1](#T1){ref-type="table"}.

###### 

Patient and tumor characteristics for IG-IMRT (n = 49) and RP followed by IMRT (n = 49)

  **Characteristics**                                     **Total**             **RP + IMRT**            **IG-IMRT**         **p-value**
  ------------------------------------------------ ----------------------- ----------------------- ----------------------- ---------------
  Median age -- years \[range\]                      66.8 \[51.7-82.7\]      64.8 \[51.7-82.7\]      70.2 \[53.3-82.4\]     \< 0.001 ^£^
  Median follow-up -- months \[range\]              56.6 \[18.22-115.1\]     51.5 \[18.2-115.1\]     62.2 \[25.5-106.0\]   
  Clinical T stage                                        1.0 ^\$^                                                         
  T1c -- n (%)                                           60 (61.2%)              30 (61.2%)              30 (61.2%)        
  T2 -- n (%)                                             4 (4.1%)                2 (4.1%)                2 (4.1%)         
  T2a -- n (%)                                           14 (14.3%)               7 (14.3%)               7 (14.3%)        
  T2b -- n (%)                                           20 (20.4%)              10 (20.4%)              10 (20.4%)        
  Gleason score on biopsy                                  1.0 ^μ^                                                         
  ≤ 6 -- n (%)                                           58 (59.2%)              29 (59.2%)              29 (59.2%)        
  7 -- n (%)                                             40 (40.8%)              20 (40.8%)              20 (40.8%)        
  Pretherapeutic PSA                                     0.632 ^\#^                                                        
  Median value -- ng/mL \[range\]                     8.7 \[1.7 - 32\]        8.7 \[2.7 - 29\]        8.7 \[1.7 - 32\]     
  Risk group                                              1.0 ^\$^                                                         
  Low                                                    30 (30.6%)              15 (30.6%)              15 (30.6%)        
  Intermediate                                           62 (63.3%)              31 (63.3%)              31 (63.3%)        
  High                                                    6 (6.1%)                3 (6.1%)                3 (6.1%)         
  Concomitant hormones with radiation                      1.0 ^μ^                                                         
  n (%)                                                  20 (20.4%)              10 (20.4%)              10 (20.4%)        
  Adjuvant hormones with radiation                        0.564 ^μ^                                                        
  n (%)                                                  14 (14.3%)               6 (12.2%)               8 (16.3%)        
  Mean dose of radiotherapy                                                                                                
  Prostatic fossa -- median value (Gy) \[range\]    70.0 \[31.4 -- 79.8\]   66.0 \[31.4 -- 70.3\]   77.4 \[73.0 -- 79.8\]   \< 0.001 ^\#^
  Rectum -- median value (Gy) \[range\]             38.1 \[4.8 -- 61.1\]    36.0 \[4.8 -- 57.1\]    39.3 \[26.5 -- 61.1\]    0.061 ^\#^
  Bladder -- median value (Gy) \[range\]            32.7 \[15.5 -- 67.3\]   43.6 \[16.8 -- 63.7\]   31.3 \[15.5 -- 67.3\]   \< 0.001 ^£^

\* Union for International Cancer Control classification 2002 (6^th^ edition); £ Student's test; \$ Fisher's exact test; \# Kruskall Wallis test; μ: Chi2.

*IG-IMRT*: Image-guided intensity modulated radiotherapy; *RP*: radical prostatectomy, *PSA*: Prostate Specific Antigen.

Surgery and postoperative IMRT (n = 49)
---------------------------------------

For the group of patients who underwent a RP (n = 49), the pathological stage was pT2b for 3 patients (6.1%), pT2c for 18 patients (36.7%), pT3a for 16 patients (32.6%) and pT3b for 12 patients (24.5%). Therefore, after comparisons with pretherapeutic clinical stage as defined using digital rectal examination, and sextant-biopsy, all of the tumors were upstaged after pathological evaluation of the specimen. Pelvic lymph node dissection was performed in 40 patients (81.6%) of whom none had nodal involvement according to the pathology examination. A microscopic positive surgical margin was observed in 30 patients (65.2%). The Gleason score evaluated on specimen was ≤ 6 in 19 patients (38.7%), 7 in 29 patients (59.2%) and ≥ 8 in 1 patient (2.0%). Comparisons between the pre and postoperative Gleason score showed that the Gleason score was upgraded after the pathological examination of the specimen in 17 patients (34.5%). Postoperative PSA was detectable for 22 patients (45.8%).

The median delay between surgery and postoperative IMRT was 11.4 months \[2.9-69.6\]. Seventeen patients (35%) underwent aRT whereas 32 patients (65%) had early sRT. The median PSA value before postoperative IMRT was 0.28 ng/mL \[0.00 -- 6.99\]. Post-operative IMRT delivered daily fractions of 2 Gy, (5 fractions a week) using the same protocol for all the patients.

Late toxicity (n = 96)
----------------------

The median dose delivered in the IG-IMRT group was 77.4 Gy \[73.0-79.8\]. In the postoperative setting, the median radiation dose was 66.0 Gy \[31.4-70.3 Gy\].

We found no difference between the group of patients treated with exclusive IG-IMRT and the group of patients treated with RP followed by postoperative IMRT for gastrointestinal toxicity or genitourinary toxicity. The rates of late grade ≥ 2 gastrointestinal toxicity at 5 years were 0% (0/49)in the IG-IMRT group and 4% (2/47) in the RP + IMRT group, whereas the rates of late grade ≥ 2 genitourinary toxicity were 42% (21/49) and 42% (20/47) respectively (p = 0.976). Late grade 2 or higher toxicities are summarized in Table [2](#T2){ref-type="table"}.

###### 

Late toxicity for localized prostate cancer patients with respect to treatment arm (IG-IMRT vs. RP followed by IMRT)

  **Toxicity**        **Total**    **IG-IMRT**   **RP + IMRT**   **p-value**
  ------------------ ------------ ------------- --------------- -------------
  Genitourinary         0.145                                   
  G0                  30 (31.3%)   11 (22.5%)     19 (40.4%)    
  G1                  25 (26.0%)   17 (34.7%)      8 (17.0%)    
  G2                  24 (25.0%)   12 (24.5%)     12 (25.5%)    
  G3                  17 (17.7%)    9 (18.4%)      8 (17.0%)    
  G4                      \-           \-             \-        
  Gastrointestinal      0.095                                   
  G0                  85 (88.5%)   42 (85.7%)     43 (91.5%)    
  G1                   9 (9.4%)     7 (14.3%)      2 (4.3%)     
  G2                      \-           \-             \-        
  G3                   2 (2.1%)        \-          2 (4.3%)     
  G4                                   \-             \-               

Freedom from biochemical failure
--------------------------------

In the entire cohort of patients (n = 98), 12 patients had failed biochemically (3 patients in the IG-IMRT group and 9 patients in the RP + IMRT group). The median Kaplan Meier reverse follow-up for the entire cohort was 56.6 months (CI95%: \[49.6-61.2\]); range: (18.22-115.1), 51.5 months in the RP + IMRT group (CI95%: \[39.2-59.5%\]; range (18.2-115.1) months) and 62.2 months in the IG-IMRT group (CI95%: \[52.3-69.5\]; range (25.5-106.0) months).

The 3-year and 5-year FFF rates for the entire cohort were 91.7% \[84.0%-95.7%\] and 85.6% \[75.7%-91.7%\]. In the IG-IMRT group, the 3-year and 5-year FFF rates were 95.9% \[84.5%-98.9%\] and 93.1% \[80.0-97.8\], respectively. In the group of radical prostatectomy, the FFF rates were significantly lower when using either a PSA threshold of ≥ 0.1 ng/mL : 87.6% \[74.5%-94.2%\] at 3-years and 76.5% \[58.3-87.5\] at 5-years (p = 0.031) or with a PSA threshold of ≥ 0.2 ng/mL : 87.5% \[74.3%-94.2%\] at 3-years and 75.2% \[55.7-87.0\] at 5-years (p = 0.032).

Time to biochemical relapse-free curves according to the treatment sequence is represented in Figure [1](#F1){ref-type="fig"}. In univariate analysis, RP followed by postoperative IMRT was the only predictive factor of an increased biochemical failure rate after treatment (Table [3](#T3){ref-type="table"}).

![Kaplan Meier curves comparing biochemical relapse-free survival for localized prostate cancer patients treated with exclusive IG-IMRT and radical prostatectomy followed by IMRT calculated from the start of any treatment (p = 0.031, univariate analysis).](1748-717X-7-158-1){#F1}

###### 

Three and 5-year FFF rates from the start of any treatment with comparison of patient-, tumor- and treatment-related characteristics (univariate analysis)

  **Characteristics**    **Events (n)/patients (n)**   **3-year FFF rates - % \[range\]**   **5-year FFF rates - % \[range\]**   **Log-rank test**
  --------------------- ----------------------------- ------------------------------------ ------------------------------------ -------------------
  Treatment                       0.0311\*                                                                                      
   IG-IMRT                          3/49                    95.87% \[84.49%-98.95%\]             93.14% \[79.96%-97.76%\]       
   RP + IMRT                        9/49                    87.61% \[74.48%-94.24%\]             76.46% \[58.31%-87.50%\]       
  Age                                                                                                                           
   ≤ 66.8 years                     5/49                    91.74% \[79.47%-96.82%\]             88.35% \[73.58%-95.12%\]              0.595
   \> 66.8 years                    7/49                    91.59% \[79.08%-96.76%\]             83.00% \[67.17%-91.65%\]       
  Tumor stage                                                                                                                   
   T1                               8/60                    91.44% \[80.61%-96.35%\]             84.37% \[70.75%-91.99%\]              0.758
   T2                               4/38                    92.11% \[77.49%-97.38%\]             87.72% \[69.57%-95.38%\]       
  Gleason score                                                                                                                 
   ≤ 6                              5/58                    96.52% \[86.80%-99.12%\]             89.15% \[75.57%-95.40%\]              0.135
   7                                7/40                    84.68% \[68.98%-92.82%\]             81.29% \[64.45%-90.69%\]       
  Pretherapeutic PSA                                                                                                            
   ≤ 8.7 ng/mL                      4/49                    93.83% \[82.08%-97.97%\]             90.99% \[77.46%-96.57%\]              0.250
   \> 8.7 ng/mL                     8/49                    89.55% \[76.67%-95.52%\]             80.69% \[64.58%-90.01%\]       
  Concomitant ADT                                                                                                               
   No                               12/78                   89.53% \[80.13%-94.63%\]             82.02% \[70.12%-89.52%\]              0.070
   Yes                              0/20                        100 \[ND -- ND\]                     100 \[ND -- ND\]           
  Adjuvant ADT                                                                                                                  
   No                               12/84                   90.29% \[81.51%-95.03%\]             83.44% \[72.36%-90.36%\]              0.156
   Yes                              0/14                        100 \[ND -- ND\]                     100 \[ND -- ND\]                     

*FFF*: Freedom from biochemical failure; *ADT*: androgen deprivation therapy; \* the definition of biochemical failure in the RP + IMRT group is a *PSA* threshold of ≥ 0.1 ng/mL.

Discussion
==========

In the absence of a randomized trial directly comparing RP with treatment by radiation therapy in men with localized PCa, it is often difficult for patients and physicians to determine which treatment option to pursue for localized PCa.

The results from several larger retrospective trials indicate that biochemical and survival outcomes with RP, dose-escalated external beam radiotherapy and brachytherapy are similar \[[@B13],[@B14],[@B22]\]. In a large trial that compared RP with exclusive radiotherapy in 1682 men with PCa, the strongest predictive factors of a biochemical relapse were the pretherapeutic PSA value, the Gleason score on biopsy, the clinical T-stage and the radiation dose for patients who underwent radiation therapy \[[@B11]\]. Previous studies in which the dose of radiotherapy delivered to the prostate was suboptimal (\< 72 Gy) showed worse outcomes with external radiotherapy than with RP for low- or intermediate-risk PCa patients \[[@B11],[@B13],[@B14]\].

Dose escalation up to \> 74 Gy benefits all risk-groups of patients in terms of biochemical relapse-free survival \[[@B16],[@B23]\]. With a longer follow-up, a positive impact of dose escalation on survival has been also observed \[[@B24]\]. Intensity modulated radiation therapy to deliver dose-escalated radiotherapy gives promising biochemical outcomes with a dramatic decrease in rectal toxicity. It is therefore widely accepted as safe for PCa patients selected for exclusive radiotherapy \[[@B25]\].

When the prostate has not been removed, IGRT with or without IMRT, has also demonstrated similar outcomes with very low rates of late grade ≥ 3 gastrointestinal and genitourinary toxicity in less than 5% of the patients, respectively \[[@B18]\].

In-parallel, improvements in surgery and pretherapeutic imaging have been tested so that even intermediate or high-risk patients at baseline could also benefit from RP. Nevertheless, approximately 15-25% of men who undergo RP for localized prostate cancer will experience biochemical failure (i.e. men with features of more severe disease in the pathological evaluation of the specimen, such as extension through the capsule, seminal vesicle involvement, a positive surgical margin and/or a a higher Gleason score). Adjuvant postoperative radiotherapy in this setting improves biochemical control \[[@B6],[@B26]\]. Some authors even advocate that early salvage radiotherapy with a careful monitoring of PSA postoperatively provides similar results, thereby limiting the adverse urinary effects of postoperative radiotherapy \[[@B9]\].

Previous clinical studies have attempted to compare biochemical outcome in RP and exclusive radiotherapy in patients with a clinically localized PCa \[[@B11],[@B12],[@B14],[@B22]\]. Although larger than our study, all of the previously published retrospective comparisons of RP and exclusive radiotherapy for localized PCa suffer from a heterogeneous design with no distinction between patients who did or did not require adjuvant radiation. In the absence of a randomized trial, we chose to perform a matched-pair analysis by selecting patients who required postoperative radiotherapy after pathologically proven poor characteristics. By using this methodology, we found that patients treated with exclusive IG-IMRT had better 5-year FFF than those treated with RP followed by postoperative IMRT. Despite the strengths of our study, such as the matched-pair comparison on risk-groups as defined clinically at baseline, our study suffers from some limitations. Major limitations arise from the retrospective design, with drawbacks related to selection bias and sample size. Some could argue that the likelihood of pathologically unexpected high-risk features is unknown in the IG-IMRT group. Nevertheless, we believe that the findings of this pragmatic study will be helpful in the modern era of IMRT and IGRT, in that they suggest how the results of RP can be improved, as the choice of treatment always depends on baseline clinical characteristics. Moreover, multiparametric MRI is part of the work-up procedure in our institution. Multiparametric MRI has dramatically improved the detection of T3 \[[@B27]\]. We therefore assumed that the patients in the IG-IMRT group closely matched those in the RP + IMRT group. Although we found that IMRT, given with combined IGRT or postoperatively without image guidance, resulted in very low rates of toxicity in both groups, our results suggest that image guidance could play a major role in local control. The incremental value of IGRT combined with exclusive IMRT suggests that IG-IMRT should also be tested in the postoperative setting. With the advent of on-board CT imaging such as Cone Beam Computed Tomography (CBCT), postop IGRT based on soft tissues (i.e. the prostate bed) gives more accurate radiation delivery in the postop setting than does 2D images of the bony landmarks. Preliminary experience with RP followed by postoperative IGRT using 3D CBCT for repositioning based on soft tissues has already been reported with promising findings compared with 2D images \[[@B28]\]. It could also be expected that results from postoperative radiotherapy could be improved by escalating the dose of radiotherapy. A dose effect has also been clearly demonstrated in this setting with a significant impact on biochemical control for doses above 72 Gy \[[@B29],[@B30]\].

Conclusions
===========

Patients with localized PCa at diagnosis who were treated with IG-IMRT or RP + IMRT had low rates of late gastrointestinal and genitourinary toxicity. Nevertheless, patients treated with high dose IG-IMRT had significantly a better 5-year FFF, suggesting that the results of postoperative IMRT could be improved by implementing IGRT technique and/or increasing the dose of radiation above 72 Gy.
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